Search research articles
Contact Us
Filters
Showing results (461-470 of 469) with videos related to
Page
of 47
Sort By:
You have reached the last page of results.
This site can display upto 469 results.
Nature
|
March 20, 2009
Histone modifications at human enhancers reflect global cell-type-specific gene expression
Nathaniel D Heintzman, Gary C Hon, R David Hawkins, et al.
JCO Oncology Practice
|
October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
Anand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Haematologica
|
May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms
Beata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Blood
|
January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis, Farhad Ravandi, Eunice S Wang, et al.
The Lancet. Oncology
|
August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Blood Advances
|
November 7, 2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Saurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, et al.
The New England Journal of Medicine
|
June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 29, 2018
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
Saurabh Chhabra, Ying Liu, Michael T Hemmer, et al.
Page
of 47
Search research articles
Search
Showing results (461-470 of 469) with videos related to
Sort By:
Page
of 47
You have reached the last page of results.
This site can display upto 469 results.
Nature
|
March 20, 2009
Histone modifications at human enhancers reflect global cell-type-specific gene expression
Nathaniel D Heintzman, Gary C Hon, R David Hawkins, et al.
JCO Oncology Practice
|
October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia
Anand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Haematologica
|
May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms
Beata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Blood
|
January 29, 2011
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis, Farhad Ravandi, Eunice S Wang, et al.
The Lancet. Oncology
|
August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
Farhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Blood Advances
|
November 7, 2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Saurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, et al.
The New England Journal of Medicine
|
June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
Courtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 29, 2018
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
Saurabh Chhabra, Ying Liu, Michael T Hemmer, et al.
Page
of 47